MIM
CARM

Monashee Investment Management’s Carisma Therapeutics CARM Stock Holding History

Monashee Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,000
Closed -$300K – 127
2019
Q2 		$300K Buy
+10,000
New +$299K 0.08% 138

Other funds holding CARM

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Monashee Investment Management's CARM Position: Q3 2019 in Review

Monashee Investment Management sold out of Carisma Therapeutics (CARM) in Q3 2019, closing a stake of 10,000 shares — an estimated $300K sold.

Monashee Investment Management first reported a position in CARM in Q2 2019 and held it in 1 quarter. The position peaked at $300K in Q2 2019. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2019.

  • Monashee Investment Management reported no remaining Carisma Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Monashee Investment Management sold 10,000 Carisma Therapeutics shares in Q3 2019, an estimated $300K.
  • Monashee Investment Management first reported a position in Carisma Therapeutics in Q2 2019 and held it in 1 quarter.
  • Monashee Investment Management's Carisma Therapeutics position peaked at $300K in Q2 2019.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2019.

Based on Monashee Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.